Introduction
Increasing attention is being paid to the impact of the metabolic syndrome, which comprises a constellation of metabolic abnormalities including centrally distributed obesity, decreased high-density lipoprotein cholesterol (HDL-C), elevated triglycerides (TG), elevated blood pressure (BP), and hyperglycemia or diabetes. These metabolic abnormalities are interrelated, with the presence of abdominal visceral fat contributing to the development of the other abnormalities in the syndrome (1, 2) . Various definitions of the metabolic syndrome have been published (Grundy et al. (3) and the International Diabetes Federation [The IDF Consensus Worldwide Definition of Metabolic Syndrome, 2005, available at: http:// www.idf.org/]), and in 2005 new criteria for diagnosing it in Japanese patients were established by expert panels of the Japanese Society of Internal Medicine (1, 2) .
A clear relationship between the metabolic syndrome and an increased risk for the development of incident cardiovascular disease (CVD), CVD mortality, and all-cause mortality has been demonstrated by prospective studies in general Western populations (4) (5) (6) (7) (8) (9) (10) (11) (12) . Although there is little similar evidence in the Japanese population to date, two studies (13, 14) suggest that the metabolic syndrome is a robust risk factor for CVD in this population, with as high as a 2.2-fold increased risk.
Systolic blood pressure increases the risk of cardiovascular events in a linear fashion, as shown by a number of metaanalyses of large-scale clinical trials (15) (16) (17) (18) . In Western hypertensive populations, the prognostic impact of the metabolic syndrome on CVD events has been demonstrated by a few studies (19, 20) ; in contrast, few large-scale studies are available in the Japanese hypertensive population. In the Hisayama epidemiologic study, a significant excess risk of CVD events was found in persons with hypertension plus metabolic syndrome compared with those without metabolic syndrome (14) . However, this finding is based on only 548 persons with hypertension. Therefore, a large-scale study is needed to confirm the risk of CVD in persons with hypertension and the metabolic syndrome.
The OMEGA (Olmesartan Mega Study to Determine the Relationship between Cardiovascular Endpoints and Blood Pressure Goal Achievement) study, a prospective, largescale, observational study, was designed to examine the relationship between the incidence of CVD and achieved BP, metabolic syndrome, lifestyle factors (e.g., intake of high-salt foods), and other risk factors for CVD. The OMEGA study was initiated as a post-marketing surveillance study by Daiichi Sankyo Co., Ltd. in compliance with the Ministry of Health, Labour and Welfare regulations.
Methods

Patient Recruitment
Eligible for inclusion in the study entry were men and women who were 50 to 79 years old, diagnosed with hypertension by their physician and receiving treatment in outpatient clinics, and who had not been treated with the angiotensin II receptor blocker olmesartan medoxomil before study registration. Exclusion criteria were 1) history of myocardial infarction, stroke, coronary artery bypass graft surgery or percutaneous coronary intervention within 6 months of study enrollment, 2) scheduled coronary intervention at study enrollment, 3) congenital or rheumatic heart disease, 4) severe arrhythmia, 5) severe liver or renal disease, 6) current cancer treatment, and 7) pregnancy or the ability to become pregnant. Each patient was informed of the purpose and methodology of the study, the right to withdraw from the study at any time, and the measures for privacy protection. After providing informed consent and being prescribed olmesartan, patients were enrolled using the central electronic data capturing system. The study was registered at http://www.clinicaltrials.jp/ with the identification number JapicCTI-050002.
Lifestyle Questionnaire
A self-administered lifestyle questionnaire was completed by each patient at the baseline examination, to provide information on cigarette smoking, alcohol intake, physical activity, and frequency of intake of specific foods (high-salt foods, fruits, fish, and soybean products) known to have an effect on hypertension and cardiovascular disease. Smoking status was classified as current smoker, ex-smoker (quit smoking within the previous year), ex-smoker (quit smoking > 1 year ago), or never smoker. Alcohol status was classified as current drinker, occasional drinker, ex-drinker, or never drank alcohol. Physical activity was classified into taking exercise, defined as rapid walking for > 30 min at least twice/week, or the equivalent, during the previous year, or not exercising. Food intake was assessed for sodium, potassium, and soybean/fish content for each patient.
Endpoints
The primary endpoint was the incidence of CVD, defined as the occurrence of stroke, subarachnoid hemorrhage, myocardial infarction, angina pectoris requiring hospitalization including coronary intervention, or sudden and unexpected death (21, 22) . Stroke and subarachnoid hemorrhage were diagnosed as a loss of neurologic function caused by an ischemic or hemorrhagic event with residual symptoms at least 24 h after onset or leading to death plus documentation by computed tomography or magnetic resonance imaging. Myocardial infarction was diagnosed as ischemic symptoms plus changes in biochemical markers of myocardial necrosis (typical rise and gradual fall of troponin T or troponin I (23) level or rapid rise and fall of creatine kinase MB isoenzyme [CK-MB] and/or electrocardiogram changes indicative of ischemia). Sudden and unexpected death was defined as death occurring within 24 h after the onset of severe symptoms or without severe symptoms at last physician visit and no known non-cardiovascular disease as cause of death.
Treatment and Study Procedure
No restriction was placed on prior antihypertensive drug treatment, with the exception of prior use of olmesartan, or on the use of combination antihypertensive drug treatment during the study. A central electronic data capturing system was used for patient data collection. Patients were seen at least every 6 months for 3 years after initiation of olmesartan treatment, for a total of six examinations for each patient. At each visit, BP, pulse rate, laboratory tests, drugs being taken concomitantly, and the occurrence of CVD events were recorded. All adverse events were also recorded by the patient's physician.
Diagnostic Criteria for Metabolic Syndrome
The metabolic syndrome was defined according to the criteria established by the Japanese Society of Internal Medicine (1, 2) . One criterion was fulfilled at study entry, since all study patients had hypertension. Furthermore, patients meeting the additional essential criteria of the presence of central obesity with a waist circumference ≥ 85 cm for men and ≥ 90 cm for women plus dyslipidemia (serum TG≥ 150 mg/dL, HDL-C < 40 mg/dL) and/or fasting hyperglycemia (serum glucose ≥ 110 mg/dL) or diagnosis of diabetes were defined as having the metabolic syndrome.
Sample Size Determination
A sample of 12,000 patients, including drop-outs, was required to detect an increase in the incidence of cardiovascular events with an 80% power using a 0.05 level two-sided logrank test. A total of 435 events was required in 9,710 patients. Basic assumptions were a 1.3-fold increased risk with essential hypertension plus dyslipidemia and a cumulative incidence of 4% over 3 years in patients without dyslipidemia (24) (25) (26) (27) .
Statistical Analysis Plan
The Cox proportional hazards model and other statistical analyses will be used to investigate the relation between the incidence of cardiovascular events and baseline factors, including metabolic syndrome, diabetes, use of antihypertensive drug, and salt intake. In evaluating the association between on-treatment BP and the incidence of cardiovascular events, on-treatment BP will be used as a time-dependent covariate. Ancillary analyses with external data will be considered to obtain more valuable information, such as an estimation of the effect size of olmesartan in the hypertensive patients in OMEGA study compared with hypertensive patients not taking olmesartan.
Study Organization
The study organization and the members of the Medical Expert Advisory Committee of the OMEGA study are detailed in the Appendix. Data are shown as means±SD. *Physical activity: rapid walking for >30 min at least twice/week or equivalent during the previous year. patients who were registered twice and 52 patients whose physicians were no longer available because of illness or departure from the hospital were excluded from the study analyses. We report here the data for 14,841 of the 15,256 patients eligible for analysis, whose baseline data were complete as of October 31, 2007. The most frequently used initial daily dose of olmesartan was 20 mg (10,134 patients, 68.3%), followed by 10 mg (4,262 patients, 28.7%). Concomitant drug therapy was used in 9,174 patients (61.8%), antihypertensive drugs in 5,727 patients (38.6%), lipid-lowering drugs in 3,116 patients (21.0%), hypoglycemic drugs in 1,984 patients (13.4%), and aspirin or antiplatelets in 1,377 patients (9.3%). Antihypertensive drugs used were calcium channel blockers in 4,905 patients (33.1%), β-blockers in 914 patients (6.2%), and diuretics in 577 patients (3.9%). Statins were used in 2,650 patients (17.9%).
Results
Baseline Characteristics of the OMEGA Study Population
Prevalence of the Metabolic Syndrome
Of the 14,841 patients in this analysis, waist circumference data were missing for 3,043 patients and biochemical measures were missing for 490 patients-data that are required by the Japanese Society of Internal Medicine definition for the metabolic syndrome-leaving 11,308 (5,532 men and 5,776 women) for evaluation. All had hypertension as a criterion for study inclusion. The metabolic syndrome was identified in 48.1% of the men and 18.5% of the women who could be evaluated for its presence.
The contribution of high fasting plasma glucose (FPG), high TG, and low HDL-C to the diagnosis of the metabolic syndrome in the 2,663 men and 1,067 women with this diagnosis is shown in Fig. 1 . The most frequent contributor in men and women was a high FPG, followed by a high TG, and low HDL-C, which contributed little to the diagnosis of the metabolic syndrome. More men than women had all three of these components (6.0% vs. 2.9%, respectively). Figure 2 shows the contribution of each component of the metabolic syndrome to its diagnosis by sex and age. High FPG was a greater contributor to the metabolic syndrome in men in their 70s than those in their 50s, whereas high TG was a greater contributor in their 50s than in their 70s. In women, there was no difference with respect to age for the contribution of high FPG, high TG, or low HDL-C to the development of metabolic syndrome.
Discussion
In the OMEGA population, the prevalences of metabolic syndrome were 48% and 19% of the evaluable men and women, respectively, according to the criteria of the Japanese Society of Internal Medicine. The prevalence of the metabolic syndrome in other studies using the same criteria is shown in Table 3 . Although a direct comparison to our data is limited because it is not adjusted for the difference in age distribution across the populations, the prevalence of the metabolic syndrome in men and women seems to be higher in the OMEGA study than in the general population (28) (29) (30) and similar to that in a diabetic population (31) and a hypertensive one (32). The Hisayama Study (14) showed that the risk of incident CVD increased with the number of components of the metabolic syndrome present. In our study in patients with the syndrome, the greatest risk for CVD seemed to be in men, among whom there was a higher proportion with all five metabolic syndrome components than among women.
The strengths of the OMEGA study include its large number of hypertensive patients and its waist circumference data. At present, studies providing evidence regarding the prognostic value of the metabolic syndrome for CVD events are available for the Western hypertensive population (19, 20) ; in contrast, few large-scale studies are available in the Japanese hypertensive population.
Schillaci et al. (19) showed that 34% of 1,742 patients with hypertension had the metabolic syndrome, based on the modified definition of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) (3). The risk of developing cardiovascular events was still higher in patients with the metabolic syndrome than in those without, According to the Japanese definition, the cutoff points for waist circumference are 85 cm for men and 90 cm for women, whereas in the IDF definitions it is 90 cm for men and 80 cm for women. Thus, it will be possible to compare their prognostic ability for incident CVD at the end of the OMEGA study.
The Hisayama Study (14) showed that hypertension and diabetes are strong risk factors for CVD. In the analysis, the age-and sex-adjusted HR for CVD was significantly higher in hypertensive patients without metabolic syndrome (HR 1.81, 95% CI 1.35-2.43) than in patients without hypertension or metabolic syndrome. Further, a significant excess risk of CVD was found in hypertensive patients with metabolic syndrome compared with those without (HR 2.59, 95% CI 1.93-3.48). Similarly, the age-and sex-adjusted HR for CVD was significantly higher in diabetic subjects with metabolic syndrome (HR 2.75, 95% CI 1.93-3.93) than in those without diabetes or metabolic syndrome. About one-fourth of the OMEGA population was at high risk for CVD, with all having hypertension and 24% having diabetes mellitus.
In this study population, the histories of stroke, percutaneous coronary intervention, and myocardial infarction were 4.0%, 2.0%, and 1.6%, respectively. Thus, the impact of these risk factors on CVD events was limited.
About 75% of the study population had mild to moderate hypertension, which generally requires less aggressive drug treatment. However, if the metabolic syndrome confers an additional increased risk in the subset of patients with this diagnosis, it could be useful to improve risk stratification and guide therapeutic approaches.
The complete follow-up data from the OMEGA study will clarify the relationship between the incidence of cardiovascular disease and the metabolic syndrome, achieved blood pressure levels, lifestyle factors, and clinical risk factors in Japanese patients with hypertension. This will provide muchneeded information to guide treatment in these patients, in whom little evidence is available to date.
